CITIC SEC points out that PD-L1 ADC drugs combine the dual efficacy of immunotherapy and targeted ADCs, with a potential market scale expected to match the global market of over 50 billion dollars for immunotherapy drugs. The PD-L1 positivity rate for several high-incidence cancers in US markets exceeds 50%. Pfizer's PD-L1 ADC has demonstrated excellent efficacy in heavily treated populations with NSCLC and HNSCC, and its safety is controllable. Pfizer is expected to initiate two Phase III clinical trials in the second half of 2025, significantly increasing research certainty for the field. HENLIUS's PD-L1 ADC has also initiated five Phase II clinical trials in China around 2025, and it is expected to report Phase I clinical data in 2025. Therefore, attention should be paid to the clinical potential and commercial value of PD-L1 ADC.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Warren Buffett's 40 investment sayings are worth reading and re-reading.
The DeepSeek-V3 model has been updated, with comprehensive advancements in various capabilities.
Contemporary Amperex Technology: Issuance of Overseas Listed Foreign Shares (Listed in Hong Kong) has been filed with the China Securities Regulatory Commission.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
中信证券:PD-L1 ADC药物有望触及全球超500亿美元IO市场
CITIC SEC: PD-L1 ADC drugs are expected to reach a global immuno-oncology market of over 50 billion dollars.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 909
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report